

1 **Validating and modeling the impact of high-frequency rapid antigen screening on COVID-**
2 **19 spread and outcomes**

3
4 Authors: Beatrice Nash^{1,2*}, Anthony Badea^{1,3*}, Ankita Reddy^{1,4*}, Miguel Bosch^{1,5}, Nol Salcedo¹,
5 Adam R. Gomez¹, Alice Versiani⁶, Gislaine Celestino Dutra Silva⁶, Thayza Maria Izabel Lopes
6 dos Santos⁶, Bruno H. G. A. Milhim⁶, Marilia M Moraes⁶, Guilherme Rodrigues Fernandes
7 Campos⁶, Flávia Quieroz⁶, Andreia Francesli Negri Reis⁶, Mauricio L. Nogueira⁶, Elena N.
8 Naumova⁷, Irene Bosch⁸, Bobby Brooke Herrera^{1,9†}

9
10 *These authors contributed equally to this work.

11
12 Affiliations:

13 ¹E25Bio, Inc., Cambridge, MA, USA

14 ²Department of Computer Science, Harvard University School of Engineering and Applied
15 Sciences, Cambridge, MA, USA

16 ³Department of Physics, Harvard University, Cambridge, MA, USA

17 ⁴Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

18 ⁵InfoGeosciences LLC, Houston, TX, USA

19 ⁶Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, Brazil

20 ⁷Division of the Nutrition Epidemiology and Data Science, Friedman School of Nutrition
21 Science and Policy, Tufts University, Boston, MA, USA

22 ⁸Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA

23 ⁹Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
24 Health, Boston, MA, USA

25

26 †Corresponding Author. BBH, email: bbherrera@e25bio.com

27

28 Short Title: Modeling rapid antigen testing on COVID-19 spread

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46 **Abstract**

47 High frequency screening of populations has been proposed as a strategy in facilitating
48 control of the COVID-19 pandemic. We use computational modeling, coupled with clinical data
49 from rapid antigen tests, to predict the impact of frequent viral antigen rapid testing on COVID-
50 19 spread and outcomes. Using patient nasal or nasopharyngeal swab specimens, we demonstrate
51 that the sensitivity/specificity of two rapid antigen tests compared to quantitative real-time
52 polymerase chain reaction (qRT-PCR) are 82.0%/100% and 84.7%/85.7%, respectively;
53 moreover, sensitivity correlates directly with viral load. Based on COVID-19 data from three
54 regions in the United States and São José do Rio Preto, Brazil, we show that high frequency,
55 strategic population-wide rapid testing, even at varied accuracy levels, diminishes COVID-19
56 infections, hospitalizations, and deaths at a fraction of the cost of nucleic acid detection via qRT-
57 PCR. We propose large-scale antigen-based surveillance as a viable strategy to control SARS-
58 CoV-2 spread and to enable societal re-opening.

59
60
61
62
63
64
65
66
67
68

69 INTRODUCTION

70 The COVID-19 pandemic has taken an unprecedented toll on lives, wellbeing, healthcare
71 systems, and global economies. As of 13 April 2021, there have been more than 136.2 million
72 confirmed cases globally with over 2.9 million confirmed deaths¹. However, these statistics and
73 the current mapping of disease spread present an incomplete picture of the outbreak largely due
74 to the lack of adequate testing, particularly as undetected infected cases are the main source of
75 disease spread²⁻⁷. It is estimated that the number of infected cases is more than 6 times greater
76 than the cases reported⁸. As of April 2021, the United States, India, and Brazil remain the top
77 three countries with the highest number of COVID-19 cases and deaths worldwide. As countries
78 begin to re-open their economies, a method for accessible and frequent surveillance of COVID-
79 19, with the necessary rapid quarantine measures, is crucial to prevent the multiple resurgences
80 of the disease.

81 The current standard of care rightfully places a strong focus on the diagnostic limit of
82 detection, yet frequently at the expense of cost and turnaround time. This approach has
83 contributed to limited population testing largely due to a dearth of diagnostic resources.
84 Quantitative real-time polymerase chain reaction (qRT-PCR) is the gold-standard method for
85 clinical diagnosis, with high sensitivity and specificity, but these tests require trained personnel,
86 expensive reagents and instrumentation, and significant time to execute^{9,10}. Facilities offering
87 qRT-PCR sometimes require a week or longer to complete and return the results to the
88 patient^{11,12}. During this waiting period the undiagnosed individual may spread the infection
89 and/or receive delayed medical treatment. Moreover, due to the cost and relative inaccessibility
90 of qRT-PCR in both resource-limited and abundant settings, large-scale screening using qRT-
91 PCR at frequent intervals remains impractical to identify infected but asymptomatic or mildly

92 symptomatic infections. Numerous studies have reported asymptomatic SARS-CoV-2 infections
93 as well as a variation in viral load within and between individuals at different time points,
94 suggesting the need for more frequent testing for informative surveillance¹³⁻¹⁸.

95 Technologies such as rapid viral antigen detection, clustered regularly interspaced short
96 palindromic repeats (CRISPR), and loop-mediated isothermal amplification (LAMP) of SARS-
97 CoV-2 provide potential large-scale screening applications, yet their implementation is stymied
98 by requirements for qRT-PCR-like accuracy before they can reach the market¹⁹. Several
99 members of the scientific and medical community have emphasized the value of widespread and
100 frequent antigen testing²⁰⁻²². In countries such as India, where the qRT-PCR resources would not
101 be sufficient to cover monitoring of the population, the use of rapid antigen tests is well
102 underway^{23,24}. In early May 2020, the United States Food and Drug Administration (FDA)
103 authorized the first antigen test for the laboratory detection of COVID-19, citing a need for
104 testing beyond molecular and serological methods. Antigen testing detects the viral proteins
105 rather than nucleic acids or human antibodies, allowing for detection of an active infection with
106 relative ease of sample collection and assay. These rapid assays – like other commercially-
107 available rapid antigen tests - can be mass-produced at low prices and be administered by the
108 average person without a laboratory or instrumentation. These tests also take as little as 15
109 minutes to determine the result, enabling real-time diagnosis and/or surveillance. Although
110 antigen tests usually perform with high specificities (true negative rate), their sensitivity (true
111 positive rate) is often lower when compared to molecular assays. While qRT-PCR can reach a
112 limit of detection as low as 10^2 genome copies per mL, rapid antigen testing detects viral protein
113 that is assumed to correlate with approximately 10^5 genome copies per mL²⁵.

114 We hypothesize that frequent antigen-based rapid testing even with lower sensitivities
115 compared to qRT-PCR - along with appropriate quarantine measures - can be more effective at
116 decreasing COVID-19 spread than less frequent molecular testing of symptomatic individuals.
117 Keeping in mind the realities of daily testing in resource-limited regions, we also hypothesize
118 that testing frequency can be adjusted according to the prevalence of the disease; that is, an
119 uptick in reported cases should be accompanied by more frequent testing. During the viral
120 incubation period, high infectivity correlates with a high viral load that can be detected by either
121 qRT-PCR or rapid antigen testing^{18,21,26-28}. Rapid tests thus optimize diagnosis for the most
122 infectious individuals. Studies also point to the relatively small window of time during an
123 individual's incubation period in which the qRT-PCR assay is more sensitive than rapid tests²¹.

124 In this study we report the clinical validation of two direct antigen rapid tests for
125 detection of SARS-CoV-2 spike glycoprotein (S) or nucleocapsid protein (N) using
126 retrospectively collected nasopharyngeal or nasal swab specimens. Using the clinical
127 performance data, we develop a modeling system to evaluate the impact of frequent rapid testing
128 on COVID-19 spread and outcomes using a variation of a SIR model, which has been previously
129 used to model COVID-19 transmission²⁹⁻³⁵. We build on this model to incorporate quarantine
130 states and testing protocols to examine the effects of different testing regimes. This model
131 distinguishes between undetected and detected infections and separates severe cases, specifically
132 those requiring hospitalization from those less so, which is important for disease response
133 systems such as intensive care unit triaging. We simulate COVID-19 spread with rapid testing
134 and model disease outcomes in three regions in the United States and São José do Rio Preto,
135 Brazil - the site of the clinical validation study - using publicly available data. To date, COVID-
136 19 modeling describes the course of disease spread in response to social distancing and

137 quarantine measures, and a previous simulation study has shown that frequent testing with
138 accuracies less than qRT-PCR, coupled with quarantine process and social distancing, are
139 predicted to significantly decrease infections^{21,29,35-39}. Godio et al. and Hou et al. use the classic
140 SEIR model to predict COVID-19 spread and dynamics. Reno et al. use this approach to predict
141 COVID-19-associated hospitalizations under social distancing policies. While SEIR models are
142 foundational for epidemiological studies, they fail to distinguish between diagnosed and
143 undiagnosed individuals. To address this limitation, Giordino et al. propose and implement a
144 SIDHARTHE model, on which our model is based, to understand disease spread in Italy, but
145 their analysis does not incorporate different testing regimes. Larremore et al. discuss how rapid
146 testing strategies, even when applied with low-sensitivity tests, are useful, as we do, when
147 applied to their S-I-R-Q-SQ model. Neither Giordino et al. nor Larremore et al. use realized
148 outbreaks to extract parameters - instead they are chosen based on informed guesses and/or
149 idealized closed systems. They also do not compare the results of their simulations with the data
150 reported, and hence the analyses are limited by their purely theoretical nature.

151 By simulating the implementation of rapid testing strategies using parameters extracted
152 from data from realized outbreaks, we are able to expand on existing insights, including:
153 predicting the effectiveness of such schema on outbreaks with differing dynamics and at varying
154 intervention times, extracting parameters to train the comprehensive SIDHARTHE-Q model, and
155 demonstrating a method that is easily applied to fit parameters for any COVID-19 outbreak given
156 a data set including daily reports of confirmed cases, current hospitalizations, and deaths. Using
157 this method, we propose and test the effectiveness of a variety of testing strategies and analyze
158 key factors affecting their success or failure. Both simulations and data-driven predictions are of
159 utmost importance to make decisions concerning an unprecedented event such as a rapidly-

160 evolving pandemic, and this is the first modeling system using publicly-available data to
161 simulate how potential public health strategies based on testing performance, frequency, and
162 geography impact the course of COVID-19 spread and outcomes.

163 Our findings suggest that a rapid test, even with sensitivities lower than molecular tests,
164 when strategically administered 2-3 times per week, will reduce COVID-19 spread,
165 hospitalizations, and deaths at a fraction of the cost of nucleic acid testing via qRT-PCR. Modern
166 surveillance systems should be well equipped with rapid testing tools to ensure that disease
167 tracking and control protocols are effective and well-tailored to national, regional, and
168 community needs.

169

170 **RESULTS**

171 **Accuracy of Direct Antigen Rapid Tests Correlate with Viral Load Levels**

172 Rapid antigen tests have recently been considered a viable source for first-line screening,
173 although concerns regarding the accuracy of these tests persist. We clinically validated two
174 different direct antigen rapid tests for the detection of either nucleocapsid protein (N) or spike
175 glycoprotein (S) from SARS-CoV-2 in retrospectively collected nasal or nasopharyngeal swab
176 specimens. Of the total number of nasal swab specimens evaluated by qRT-PCR for
177 amplification of SARS-CoV-2 N, S, and ORF1ab genes, 100 tested positive and 58 tested
178 negative (Table 1). The overall sensitivity and specificity of the rapid antigen test for detection of
179 SARS-CoV-2 N, evaluated across the nasal swab specimens, was 82.0% and 100%, respectively.
180 Of the total number of nasopharyngeal swab specimens evaluated by qRT-PCR for amplification
181 of SARS-CoV-2 N, RNA-dependent RNA polymerase (RdRp), and envelope (E) genes, 72
182 tested positive and 49 tested negative (Table 2). The overall sensitivity and specificity of the

183 rapid antigen test for detection of SARS-CoV-2 S, evaluated across the nasopharyngeal swab
184 specimens was 84.7% and 85.7%, respectively.

185 The Ct value indirectly quantifies the viral RNA copy number related to the viral load of
186 the sample for the specific assay^{40–42}. Ct values represent the number of qRT-PCR cycles at
187 which generated fluorescence crosses a threshold during the linear amplification phase; Ct values
188 are therefore inversely related to the viral load. Our data demonstrate that the sensitivity of the
189 rapid antigen tests are positively correlated to the viral load level (Table 3). For the SARS-CoV-
190 2 N and S rapid tests, the sensitivities were greater than 90% when tested with samples
191 containing Ct values <25, but plateaued to approximately 80-85% when tested with samples
192 containing Ct values between 30-40 (Table 3, Supplementary Fig.1). Taken together, the clinical
193 data shows that the rapid antigen test performs with increasing accuracy for individuals with a
194 higher viral load, and potentially the most infectious^{18,26–28}.

195

196 **An Enhanced Epidemiological SIDHRE-Q Model**

197 We propose an enhanced epidemiological modeling system, *SIDHRE-Q*, a variant of the
198 classical SIR model in order to expand our clinical validation study and to understand the effects
199 of using frequent rapid tests such as the rapid antigen test on COVID-19 outbreak dynamics.
200 The changes we make to the basic model to encompass the unique characteristics of the COVID-
201 19 pandemic are similar to those presented by Giordano et al.²⁹ (Fig. 1, Supplementary Fig. 2).
202 The differential equations governing the evolution of the *SIDHRE-Q* model and descriptions of
203 the parameter values are provided in the methods section (Equation 1, Table 4).

204 An individual that begins in Susceptible (**S**) may either transition to a Quarantine
205 Uninfected (**Q-U**) state via a false positive result or to an Infected Undetected (**I**) state via

206 interaction with an infected individual. Should an individual in **S** move into **Q-U**, they are
207 quarantined for 10 days before returning to **S**, a time period chosen based on current knowledge
208 of the infectious period of the disease and is consistent with CDC guidelines⁴³. One could also
209 conceive of an effective strategy in which individuals exit quarantine after producing a certain
210 number of negative rapid tests in the days following their initial positive result or confirm their
211 negative result using qRT-PCR. Prolonged incubation beyond 10 days is assumed to be unlikely
212 – post-quarantine risk of transmission is estimated at 1% - and hence is not included in this
213 probabilistic model.⁴³

214 State **I** contains individuals who are infected but not diagnosed. Given that those
215 diagnosed are predominantly quarantined, the undiagnosed individuals in **I** – many of which are
216 pre- or asymptomatic – interact more with the **S** population than do those in Infected Detected
217 (**D**) and transmission due to this population is critically important to modeling outbreaks.
218 Therefore, the infectious rate for **I** is assumed to be significantly larger than for **D**. Furthermore,
219 a region's ability to control an outbreak is directly related to how quickly and effectively the
220 population in **I** tests into **D**, reducing transmission rates through quarantine. From both **I** and **D**
221 individuals may transition into Recovered (**R**), accounting for the many cases of infection that
222 are never detected. This study, in particular, highlights the critical role frequency of testing,
223 along with strict quarantine, has in mitigating the spread of the disease and provides specific
224 testing strategies based on rapid tests we predict to be highly effective.

225 In this model, we assume that individuals receive a positive diagnosis before developing
226 severe symptoms and that those with symptoms severe enough to be potentially fatal will go to
227 the hospital. If an individual develops symptoms, we assume they are tested daily until receiving
228 a positive result; hence, before severe symptoms develop, they will be diagnosed with high

229 probability. Those who do not develop symptoms are tested according to the frequency of tests
230 administered to the general population. Therefore, there is no modeled connection between **I** and
231 Hospitalized (**H**) or between **I** and Extinct (**E**), i.e. dead. Removing these assumptions would
232 have negligible impact on the results as these flows are very small. We estimated the flows using
233 data on approximate total deaths due to COVID based on excess deaths in the states examined
234 and found them to be zero for greater than 10% of the days considered for each location.
235 Although lacking this information for São José do Rio Preto, we made the same assumption.

236 Should an individual test positive and transition to **D**, they may either develop serious
237 symptoms requiring care or recover. Those who develop serious symptoms and transition to state
238 **H** will then transition to either **R** or **E**. The recovered population is also tested with the same
239 frequency as the rest of the population, as infected individuals may recover without being
240 detected and the modeled testing strategy has no way of differentiating with certainty between
241 false positives and true positive, asymptomatic cases. Therefore, the Quarantined Recovered (**Q-**
242 **R**) state is introduced with the same connections to **R** as the connections between **S** and **Q-U**.
243 Though the reinfection rate of SARS-CoV-2 has been a point of recent debate, it is assumed that
244 the number of re-infected individuals is small⁴⁴⁻⁴⁸. Therefore, individuals cannot transition from
245 **R** to **S**, hence the separately categorized quarantined populations. As further knowledge
246 regarding reinfection rate develops as the pandemic continues, a flow could be added from **R** to
247 **S** with rate inversely proportional to the time for which immunity lasts.

248 We considered several variations and extensions of the *SIDHRE-Q* model. In simulations,
249 we tested additional states, such as those in the *SIDARTHE* model, which include distinctions
250 between symptomatic and asymptomatic cases for both detected and undetected populations²⁹.
251 Correlations between viral load and infectivity and sensitivity were also considered. Altogether,

252 our modeling system has been well tuned to predict the impact of high frequency rapid testing on
253 current COVID-19 spread and outcomes.

254

255 **Frequent Rapid Testing with Actionable Quarantining Dramatically Reduces Disease** 256 **Spread**

257 In order to demonstrate how strategies could affect the disease spread in different
258 geographies and demographics, we used surveillance data obtained from regions of varying
259 characteristics: the state of Massachusetts (MA), New York City (NYC), Los Angeles (LA), and
260 São José do Rio Preto (SJRP), Brazil, the site of the rapid antigen test clinical validation study.
261 These regions are also selected in our study due to the readily available surveillance data
262 provided by the local governments. We fit the model to the data from each region starting 1 April
263 2020. At this time point the disease reportedly is most advanced in NYC and least advanced in
264 SJRP, Brazil with estimated cumulative infection rates of 7.11% and 0.12%, respectively.

265 After calibrating the *SIDHRE-Q* model, the disease spread is observed with varying
266 validated rapid antigen test performances and frequencies (Fig. 2). Sensitivity (the ratio of true
267 positives to the total number of positives) and specificity (the ratio of true negatives to the total
268 number of negatives) compared to gold-standard qRT-PCR were used as measures of test
269 accuracy.

270 The rapid test frequency is varied while maintaining an accuracy of 80% sensitivity and
271 90% specificity, comparable to our clinical data collected in SJRP, Brazil. These testing
272 scenarios are then compared to symptomatic testing, in which individuals receive a rapid test
273 only when presenting symptoms, via either a rapid test or qRT-PCR. Since the primary testing
274 regimen deployed in MA, LA, NYC and SJRP, Brazil is qRT-PCR-based and focused on

275 symptomatic individuals, the symptomatic testing protocol via qRT-PCR is directly estimated
276 from the data to be the rate ν (Table 4).

277 The difference between the qRT-PCR and rapid test simulations (red and orange lines,
278 respectively) is therefore only sensitivity of testing (Fig. 2). Test outcome probability in this
279 model is a function only of whether an individual is infected and independent of other factors;
280 one can consider this a lower bound on effectiveness of a strategy, as sensitivity and infectivity
281 are often positively correlated with antigen testing. In this model with sensitivity s and frequency
282 of testing f , the probability an individual is diagnosed in a testing window is given by the
283 following:

$$284 \quad \Pr[\text{Diagnosed within days } (x, x + f)] = (1 - s)^{\frac{x}{f}-1} \cdot s. \quad (2)$$

285

286 To better understand the effect of rapid testing frequency and performance on healthcare
287 capacity and mortality rates, we simulate the testing strategy with 30%-90% sensitivity each with
288 80% or 90% specificity against the symptomatic testing strategy (Supplementary Fig. 3).

289 As per our hypothesis, frequency and symptom-based testing dramatically reduced
290 infections, simultaneous hospitalizations, and total deaths when compared to the purely
291 symptom-based testing regimens, and infections, hospitalization, and death were reduced as
292 frequency increased. Although testing every day was clearly most effective, even testing every
293 fourteen days with an imperfect test gave an improvement over symptomatic testing with qRT-
294 PCR. While the strategy works best when implemented at the very beginning of an outbreak, as
295 demonstrated by the results in SJRP, Brazil, it also works to curb an outbreak that is already
296 large, as demonstrated by the results in NYC. The difference between frequencies is more
297 noticeable when the testing strategy is applied to the outbreak in NYC, leading us to hypothesize

298 that smaller outbreaks require a lower testing frequency than larger ones; note the difference
299 between the dependence on frequency to curb a small initial outbreak in SJRP, Brazil versus a
300 large one in NYC (Fig. 3).

301 For test performance of 80% sensitivity and 90% specificity, the percent of the
302 population that has been infected in total from the beginning of the outbreak to mid-July drops
303 from 18% (MA), 11% (LA), 26% (NYC), and 11% (SJRP, Brazil) to 3%, 2%, 12%, and 0.26%,
304 respectively, using a weekly rapid testing and quarantine strategy (with regards to predictions of
305 overall infection rates, other studies based on seroprevalence and epidemiological predictions
306 have reached similar conclusions^{49,50}). If testing is increased to once every three days, these
307 numbers drop further to 1.6% (MA), 1.4% (LA), 9.5% (NYC), and 0.19% (SJRP, Brazil)
308 (Supplementary Table 1).

309 To further examine the relationship between frequency and sensitivity, we model the
310 maximum number of individuals in a given state over the 105-day time period for four
311 geographic regions (Fig. 3, Supplementary Fig. 4). In all four geographic regions, as frequency
312 of testing increases, the total infections, maximum simultaneous hospitalizations, and total deaths
313 converge to small percentages regardless of the sensitivity at high frequencies. For example, the
314 predictions show that for the outbreak in LA, a testing strategy started on 1 April of every 10
315 days using a test of sensitivity 90% would have resulted in 2.5% of the population having been
316 infected, while using a test of sensitivity 30% would require a strategy of every 5 days to achieve
317 the same number. Thus, we conclude that frequency is more important than sensitivity to control
318 the outbreak using a test-based strategy, and a large range of sensitivities prove effective when
319 testing sufficiently often (Supplementary Fig. 4-5)^{29,51}. The following subsection contains a
320 discussion of a location-based method for varying the exact frequency of testing based on

321 evolving outbreaks. Frequency of testing can be significantly reduced to effectively contain the
322 disease once the initial outbreak has been controlled; it is clear that this takes only a matter of
323 weeks (Fig. 2).

324 On the other hand, according to the specificity of the rapid test and the quarantine
325 duration, larger testing frequency result in a larger percent of the population quarantined (Fig. 2).
326 Assuming a 90% rapid test specificity and 10-day quarantine duration, for the 1-, 3- and 7-day
327 frequencies almost 48%, 24% and 12% of the population, respectively, would be quarantined.
328 This figure may be reduced with additional rules for exiting quarantine early, such as after
329 complementary testing. An example of such a strategy is that individuals who test positive are
330 required to either quarantine for two weeks or produce two consecutive negative rapid tests in
331 the two days following their positive result. Assuming 80% sensitivity and 90% specificity, those
332 individuals will reenter the public while still infected with probability 0.04. If uninfected, that
333 individual will exit quarantine after two days with probability 0.81. However, a compromise
334 between the reduction of infections and the proportion of the population in quarantine would be
335 part of the planning for the appropriate testing protocol in each community or region.

336 While high frequency may be necessary to contain a large outbreak initially, relatively
337 infrequent testing, such as every one or two weeks, is sufficient to keep controlled outbreaks
338 small, while reducing the number of quarantined individuals to less than 10% of the population
339 using a two-week mandatory quarantine.

340 Additionally, quarantine adherence is of essential importance to the success of this
341 strategy, and we assume near-perfect quarantine compliance with a small transmission rate due
342 to diagnosed individuals (Table 4). Therefore, measures are needed to ensure quarantine is
343 widely adhered to (Supplementary Fig. 8). Recent research has identified a number of ways to

344 increase quarantine compliance, including compensating for wages lost, providing quarantine
345 facilities and effective handling of the health crisis.^{52–55}

346 Additionally, while high frequency may be necessary to contain a large outbreak initially,
347 relatively infrequent testing, such as every one or two weeks, is sufficient to keep controlled
348 outbreaks small, while reducing the number of quarantined individuals to less than 10% of the
349 population using a two-week mandatory quarantine.

350
351 **A County-Based Testing Strategy Offers a Cost-effective Approach to Large-scale COVID-**
352 **19 Surveillance**

353 To examine the effects of resource-strategic testing schemes, we modeled the COVID-19
354 prevalence by varying testing frequency across counties of California. For this analysis, only
355 California was analyzed because of the accessibility of the county level data and the variability
356 of spread dynamics of the outbreaks between counties. In this scheme, the percent of active
357 infected detected individuals in a county determines the frequency of testing. We define
358 thresholds for the number of active detected infections that, when hit, initiate testing protocols of
359 different frequencies depending on the threshold hit. We first tested evenly spaced thresholds for
360 the number of detected active infections up to 1% of the population, but later adopted thresholds
361 that were determined according to Equation 3. In Equation 3, D = population of state \mathbf{D} at the
362 time of testing. T = number of active infections which, if reached, initiates everyday testing. The
363 days between tests are rounded to the closest integer value.

$$\text{Days between tests} = \max(1, 2 \log_2(T/D) + 1)$$

364
365 (3)

366 The days between tests are chosen such that the detected active infections should remain near to
367 or below T . If the initial detected active infections are greater than T , then the testing frequency
368 of 1 will cause infections to rapidly drop. Both the threshold at which everyday testing begins
369 and the coefficient of $\log_2 T/D$ can be modified to produce a strategy that is more or less frequent
370 in testing or resource effective; a range of days between tests from 14 days to 1 day are used
371 (Fig. 4a).

372 The purpose of this strategy is to tailor testing based on the specific characteristics of
373 unique outbreaks in different regions. A scan over different choices of T is shown in Fig. 4b; the
374 threshold we choose in Fig. 4a is 0.05% because it is successful in curbing the outbreak in
375 California within the time period we consider. Our analysis could be redone to select another
376 effective fine-grained strategy in other states or regions. The cost analysis is based on cost per
377 test - \$7 per rapid test and \$100 per PCR test - times number of tests used. Clearly that
378 calculation neglects the costs of storing, distributing, and administering tests, as well as
379 monitoring incoming results. The costs associated with these logistics would vary with differing
380 policies dictating the use of rapid tests; significantly, whether they would be administered at
381 home with self-reported results or in a testing facility or workplace for validation purposes. For
382 example, a company may choose to use the rapid tests to scan employees before allowing them
383 to enter the workplace, in a way similar to existing temperature checks. The cost of this
384 particular application would be minimal beyond that of the actual tests. Such costs would
385 inevitably be greater for PCR tests, which require a specialized testing facility, significant
386 equipment, and highly trained personnel.

387 Using a rapid test with a sensitivity of 80% and a specificity of 90%, the county-based
388 testing with threshold 0.05% reduces the active infections from 0.94% to 0.0005%, while the

389 uniform strategy with tests administered every 7 days results in double the number of active
390 infections (Fig. 4a). As the threshold is reduced, the total cost increases while the cumulative
391 infections, maximum percentage hospitalized, and cumulative deaths all decrease (Fig. 4b).
392 Appropriate choice of threshold is dependent on the severity of outbreaks in a specific region and
393 available resources, both logistically and fiscally. With regional data, such as that from
394 California used to produce Fig. 4b, this study can be reproduced to calculate an efficient testing
395 strategy that will effectively curb outbreaks of differing severities in any geographic entity. This
396 analysis does not include any delays in ramping testing up and down. If one were to reproduce
397 this analysis for a given testing strategy, a fixed-time delay could be introduced, depending on
398 the relevant logistical constraints.

399 Strategy B in Fig. 4 consists of qRT-PCR testing uniformly applied to the highlighted
400 population with a frequency of once weekly. The average cost per person per day is just under
401 \$15. Despite this frequency and the accuracy of qRT-PCR, the strategy does not succeed in
402 curbing the spread as fast as strategy A, which uses a testing sensitivity and specificity of 80%
403 and 90%, respectively, and testing frequency that vary between counties depending on the
404 proportion of their population that is currently infected. The total cost for strategy A is estimated
405 at a fraction of the other at \$1.53 per person per day.

406

407 **DISCUSSION**

408 In this study we examine the potential effects of a novel testing strategy to limit the
409 spread of SARS-CoV-2 utilizing rapid antigen test screening approaches. Our clinical data and
410 *SIDHRE-Q* modeling system demonstrate that 1) frequent rapid testing even at a range of
411 accuracies is effective at reducing COVID-19 spread, 2) rapid antigen tests are a viable source

412 for this strategy and diagnose the most infectious individuals, and 3) strategic geographic-based
413 testing can optimize disease control with the amount of available resources. The public has
414 witnessed and experienced symptomatic individuals being denied testing due to shortages, and
415 few testing structures for asymptomatic or mildly symptomatic individuals – a significant source
416 of disease spread. Though several factors contributed to the stymied early response measures,
417 such as lockdown and quarantine protocols and adherence, severe testing bottlenecks have been a
418 significant culprit⁵⁶⁻⁵⁸. Early control measures have been shown to decrease lives lost by several
419 orders of magnitude⁵⁹. These challenges, though exacerbated during the early months of the
420 pandemic, remain at the forefront of the public health crises.

421 Diagnosis of SARS-CoV-2 infection by qRT-PCR is the current standard of care, yet
422 remains expensive and requires a laboratory and experienced personnel for sample preparations
423 and experimentation. The turnaround time for results can be up to 10 days, preventing people
424 from either leaving quarantine if they are negative, or delaying critical care and infecting others
425 if they are positive¹². This current testing scheme moreover yields incomplete surveillance data
426 on which response efforts such as societal reopening and hospital management depend. Though
427 qRT-PCR is considered the gold-standard diagnostic method because of its high sensitivity and
428 specificity, the logistical hurdles render it unrealistic for large-scale screening.

429 As qRT-PCR remains impractical for this strategy, and rapid tests are facing regulatory
430 challenges because they do not perform with qRT-PCR-like accuracy, rapid test screening is
431 either nonexistent in several countries or symptom-based. Even under best-case assumptions,
432 findings have shown that symptom and risk-based screening strategies miss more than half of the
433 infected individuals⁶⁰. Some have argued that the need for widespread testing is overstated due
434 to the variability in test sensitivity and specificity⁶¹. Here, we present alternative large-scale

435 diagnostic tools to qRT-PCR, and show that test performance, though valuable, is secondary to
436 widespread test frequency, which is enabled by accessibility and turnaround time. Furthermore,
437 test affordability is essential for the successful implementation in communities most affected by
438 infection and will to speed up the safe opening and functioning of the vital sectors of the
439 economy.

440 Giordano et al. has modeled the evolution of SARS-CoV-2 spread, introducing a
441 diagnosed state to elucidate the importance of population-wide testing ²⁹. Larremore et al. has
442 examined how various test sensitivities and frequencies affect the reproductive number ²¹. We
443 build upon these findings to show how in affected United States and Brazil regions, population-
444 wide frequent and rapid testing schemes, with sensitivities ranging from 30%-90%, can be more
445 effective in curbing the pandemic than a PCR-based scheme. Integrating real-world surveillance
446 and clinical data into our modeling system has allowed us to incorporate regional differences -
447 such as variances in healthcare access, state health policy and adherence, state GDP, and
448 environmental factors - under the same model. Significantly, our findings hold true across
449 Massachusetts, New York City, Los Angeles, and São José do Rio Preto, Brazil. We also present
450 the economic considerations of these testing regimes, showing that widespread rapid testing is
451 more cost efficient than less frequent qRT-PCR testing. In line with these economic
452 considerations, our model demonstrates the effectiveness of a geographic-based frequent testing
453 regime, in which high disease prevalence areas receive more frequent testing than low disease
454 prevalence areas.

455 Since COVID-19 is known to affect certain demographics differently, modeling would
456 benefit from incorporating demographic information correlated with disease progression and
457 spread to define sub-models and sets of parameters accordingly. Age, pre-existing conditions,

458 job types, and density of population are examples of possible categories, each of which influence
459 the risk of contracting and/or dying from COVID-19. Further studies would benefit from
460 incorporating these ideas to better understand the effectiveness of rapid testing on identifying
461 potential super spreading events. Future public health prevention programs should use the
462 proposed modeling system to develop and test scenarios for precision testing and prevention.

463 Our findings also point to low-cost tools for implementation of this testing strategy, such
464 as a rapid antigen-based test for the detection of SARS-CoV-2 proteins. We show that the rapid
465 antigen tests perform with a range of accuracies under which disease spread can be dramatically
466 mitigated under our model. Notably, the sensitivity is correlated to the individual's viral load,
467 effectively diagnosing those who are potentially the most infectious with the highest accuracy.
468 Our findings are significant because rapid antigen tests are cheaper than qRT-PCR, can be mass
469 produced to millions per day, present results within 15 minutes, and can be administered by a
470 nonexpert without a lab or special equipment.

471 There are several policy implications for these findings. First, our model supports that
472 systems of high frequency rapid testing should be implemented as a first-line screening method.
473 This can be first enabled by a more holistic regulatory evaluation of rapid diagnostics, such that
474 policy emphasizes accessibility and turnaround time even under a range of accuracies. One can
475 imagine a less accurate, though rapid method of first-line screening in schools, public
476 transportation, and airports, or even at home, and a qRT-PCR-based method for second-line
477 screening (testing those who present severe symptoms or have been in contact with infected
478 individuals, testing in a clinical setting, etc). At home tests require a built-in digital reporting
479 capability⁶²; rapid antigen test results can be sent to local health centers with reciprocal
480 instructions regarding updated test frequency guidelines to enable adaptive testing strategies.

481 Second, our cost analysis and rapid antigen test data present a viable and potentially more cost-
482 effective method for screening. Third, our county-based testing scheme presents a possible
483 method for wide-scale screening while optimizing resources. Future studies should investigate
484 how this selective testing strategy can be applied to different location scales to further inform
485 health policy. Moreover, though our models analyze regions in the United States and Brazil,
486 similar testing strategies can be considered globally in both resource limited and abundant
487 settings due to the greater accessibility of rapid tests compared to qRT-PCR. This model can be
488 further tailored to the pandemic course as we gain further evidence regarding SARS-CoV-2 re-
489 infection rates.

490 We emphasize that integral to the effectiveness of diagnostic schemes is 1) the proper
491 adherence to quarantine and public health measures and 2) the combined use of a variety of
492 diagnostic methods including nucleic acid, antigen, and antibody tests. According to these
493 models, rapid antigen tests are an ideal tool for first-line screening. Clinical molecular tests such
494 as qRT-PCR are vital to the diagnostic landscape, particularly to re-test suspected cases that were
495 negative on the rapid test. Because rapid tests present a higher rate of false negatives, methods
496 such as qRT-PCR remain integral to second-line screening. Antibody tests provide important
497 information for immunity and vaccination purposes as well as epidemiological surveillance. This
498 model also assumes that individuals will quarantine themselves before being tested and for 10
499 days following a positive diagnostic result and will not be infected while waiting for the qRT-
500 PCR results. It is important to acknowledge the working definition of quarantine. The states
501 containing quarantined individuals (Q_U , Q_R and D) are defined as consisting of a population that
502 is meant to be quarantined, not a population that is necessarily in perfect compliance with the
503 mandate that they remain fully isolated from the population. Quarantine is assumed to be

504 imperfectly executed and the model accounts for a small, tunable interaction between
505 quarantined states and the general population, hence it is conservative.

506 There are important limitations to be considered in this model. Differences in disease
507 reporting between the geographical regions and the incomplete nature of COVID-19 surveillance
508 data, often due to the lack of testing or delays in reporting, are not considered in the model. It is
509 imperative that the testing results, hospitalization and death statistics, and changes in protocol are
510 reported in real-time to scientists and policy makers so that models can be accurately tuned as the
511 pandemic develops. Moreover, delays required to ramp testing strategies up or down are not
512 considered. Infectivity variations between individuals is also not applied to this model, and
513 future clinical studies should gather data on asymptomatic presenting COVID-19 cases. Non-
514 compliant quarantine behaviors and possible infections during testing waiting times are also not
515 included in the calculations. The model also does not take into account infrastructural
516 limitations, such as hospital capacity and testing space, which depend on factors beyond the
517 scope of this analysis. Though the rapid antigen test offers several advantages such as
518 affordability, fast turnaround time, and ease of mass production, we are assuming that there are
519 systems in place to implement frequent and safe low-cost screening across different communities
520 and settings.

521 Our model underscores the need for a point-of-care or at-home test for frequent
522 screening, particularly as lockdown restrictions ease. Regulatory agencies can work towards
523 evaluating rapid tests to alternative standards other than comparison to high sensitivity molecular
524 diagnostics, as our model shows that frequency and scale of testing may overcome lower
525 sensitivities. Rather, we can refocus policy to implement first-line screening that optimizes
526 accuracy with efficiency and equitability.

527

528

529 **METHODS**

530 **Development of Direct Antigen Rapid Tests for the Detection of SARS-CoV-2**

531 We developed a direct antigen rapid test for the detection of the nucleocapsid protein or
532 spike glycoprotein from SARS-CoV-2 in nasal or nasopharyngeal swab specimens as previously
533 described⁶³. Briefly, the rapid antigen tests are immunochromatographic format with a visual
534 readout using anti-N or anti-S mouse monoclonal antibodies (E25Bio, Inc., Cambridge, MA,
535 USA) that are either coupled to 40 nm gold nanoparticles (Abcam, Cambridge, UK) or adsorbed
536 to nitrocellulose membranes (Sartorius, Goettingen, Germany). Each rapid antigen test has a
537 control area adjacent to the paper absorbent pad; the control is an anti-mouse Fc domain
538 antibody (Leinco Technologies, Fenton, MO, USA) that will capture any of the antibody-
539 conjugated gold nanoparticles to generate a control visual signal. A visual signal at the test area
540 reflects SARS-CoV-2 N or S that is “sandwiched” between an anti-N or anti-S antibody
541 adsorbed to the nitrocellulose membrane and a second anti-N or anti-S antibody covalently
542 coupled to visible gold nanoparticles.

543

544 **Validation of Direct Antigen Rapid Test for the Detection of SARS-CoV-2**

545 In a retrospective study of nasal swab specimens from human patients, we compared the
546 accuracy of the rapid antigen test for detection of SARS-CoV-2 N to the viral loads of
547 individuals. All individuals were symptomatic between 1-10 days of fever. Nasal swab
548 specimens (n=158) were tested following approved human subjects use protocols. The nasal
549 swab specimens were banked frozen from suspected patients submitted to PATH for routine

550 COVID diagnosis. Prior to using the rapid test, the nasal swab specimens were validated by
551 qRT-PCR using the FDA EUA ThermoFisher/AppliedBiosystems TaqPATH COVID-19 Combo
552 Kit (ThermoFisher, Waltham, MA USA). The primary study under which the samples and data
553 were collected received ethical clearance from the PATH Research Ethics Committee, protocol
554 number 00004244; all participants provided written informed consent for the use of the samples.
555 The nasal swab specimens were de-identified, containing no demographic data, prior to analysis,
556 and the experiments were performed in accordance with relevant guidelines and regulations.

557 The nasal swabs were originally collected in 1 mL PBS, where 50 μ l was mixed with 50
558 μ l of Solution Buffer (0.9% NaCl and 0.1% Triton X-100). The 100 μ l mixture was then
559 pipetted onto the rapid antigen test for SARS-CoV-2 N detection and allowed to react for 15
560 minutes. After processing of the rapid antigen test, the visual positive or negative signal was
561 documented.

562 Additionally, in a retrospective study of nasopharyngeal swab specimens from human
563 patients, we compared the accuracy of the rapid antigen test to the viral load of individuals.
564 Nasopharyngeal swab specimens (n = 121) were tested in Brazil following approved human
565 subjects use protocols. The age of study participants ranged from 1 to 95 years with an overall
566 median of 37 years (interquartile range, 27–51 years), and 62% were female. All individuals
567 were symptomatic between 1-10 days of fever. The demographic summary of the patients are
568 included in Supplementary Table 2. The nasopharyngeal swab specimens were banked
569 refrigerated or frozen samples from suspected patients submitted to the lab for routine COVID
570 diagnosis. Prior to using the rapid test, the nasopharyngeal swab samples were validated by qRT-
571 PCR using GeneFinder™ COVID-19 Plus RealAmp Kit (OSANGHealthcare, Anyang-si,
572 Gyeonggi-do, Republic of Korea I). The primary study under which the samples and data were

573 collected received ethical clearance from the Faculdade de Medicina de São José do Rio Preto
574 (FAMERP), protocol number 31588920.0.0000.5415; all participants provided written informed
575 consent for the use of the samples. All excess samples and corresponding data were banked and
576 de-identified prior to the analyses, and the experiments were performed in accordance with
577 relevant guidelines and regulations.

578 Nasopharyngeal swab specimens (1 mL) were concentrated using Vivaspin 500
579 centrifugal concentrators (Sartorius, Goettingen, Germany) at 12,000 x g for 10 minutes. The
580 concentrated nasopharyngeal swab specimen retentate was transferred to a collection tube and
581 the rapid antigen test for SARS-CoV-2 spike detection was inserted into the tube with the
582 retentate and allowed to react for 15 minutes. After processing of the rapid antigen test, the
583 visual positive or negative signal was documented.

584 Both nasal and nasopharyngeal swabs were used for the detection of SARS-CoV-2 N and
585 S, respectively. Some studies have shown higher efficacy of nasopharyngeal swabs for PCR
586 tests; the similar results between our two cohorts are likely due to the different proteins being
587 detected^{64,65}.

588

589 **Data for Modeling**

590 As of August 2020, the United States and Brazil have the highest number of confirmed
591 COVID-19 cases and deaths worldwide, with both countries reporting their first case on 26
592 February 2020)¹. Although several affected US regions could have been modeled, we look at data
593 from Massachusetts, New York, and Los Angeles: these regions each contained “hotspots”, or
594 areas of surging COVID-19 cases, at different points in time during the pandemic and have
595 publicly available government-provided surveillance data. Our model is fit using data over 105

596 days beginning on April 1 for Fig. 2 and Fig. 3, and 105 days beginning on April 10 for Fig. 4
 597 (see “Modeling Parameters” in Methods). In order to understand the various testing proposals on
 598 a global scale, we performed our clinical study in and expanded the modeling study to Brazil.
 599 The specific data we use to fit our model are cumulative confirmed cases, total deaths, and
 600 number of daily hospitalizations due to COVID-19. This surveillance data was retrieved from
 601 government-provided online databases⁶⁶⁻⁷².

602

603 **Modeling Parameters**

604 Equation 1 below provides the exact differential equations governing the model.

$$\begin{aligned}
 \frac{dS}{dt} &= -S(\alpha I + \eta D + \gamma) && +\psi Q_U \\
 \frac{dI}{dt} &= -I(\epsilon + \lambda + \nu) && +S(\alpha I + \eta D) \\
 \frac{dD}{dt} &= -D \left(\frac{I + D}{D} \mu + \rho \right) && +I(\nu + \epsilon) \\
 \frac{dH}{dt} &= -H(\sigma + \tau) && +\mu(D + I) \\
 \frac{dE}{dt} &= && +\tau H \\
 \frac{dR}{dt} &= -\gamma R && +\rho D + \lambda I + \sigma H + \psi Q_R \\
 \frac{dQ_U}{dt} &= -\psi Q_U && +\gamma S \\
 \frac{dQ_R}{dt} &= -\psi Q_R && +\gamma R
 \end{aligned}
 \tag{1}$$

605

606 From Table 4 describing each parameter, note that each of their values are the inverse of the
 607 average rates at which a transition is made. For example, the term $\frac{1}{\psi}$ is set equal to the
 608 population exiting quarantine per day, with $\frac{1}{\psi}$ days. The assumption made is that the
 609 distribution of time already spent in quarantine is approximately uniform among the quarantined
 610 population at any given time. The uniform rate approximation breaks down during periods when
 611 flows between states are changing rapidly within a matter of days, such as in early stages of the

612 pandemic. The result of running the model with fixed infection and quarantine times as well as a
613 discussion of how that change is incorporated in Supplementary Fig. 9. The mean value method
614 of assigning values to parameters is standard in epidemiological modeling^{29,73}.

615 In order to determine the numerical values of the parameters defining the flows between
616 states, we use a least squares regression to find fits for each seven day interval. All data points
617 within each interval and from each data set are fit collectively within each interval (the resulting
618 fits do not represent the mean of separately calculated fits). This procedure allows the model to
619 take into account the time dependent nature of the parameters, which rely on factors such as
620 social distancing regulations and changes in testing capacity. We also fit window sizes between
621 1 and 21 days and find that while the fit degrades with larger window size, the overall shape of
622 the curves do not change. We choose seven days assuming policy changes take a week to
623 become effective and that reasonably parameters can be expected to change within this time
624 period without causing problems with overfitting. Also, the seven day window size accounts for
625 the fact that often data is not reported as diligently over the weekend. Time series of the values
626 of the parameters for the geographic locations discussed in this paper are included in
627 Supplementary Fig. 6.

628 Given the restrictions on data available for the populations of various states, varying all
629 of the parameters results in an over parameterized system. Therefore, a subset of the model
630 parameters are fit while the others are either extracted from other sources; see Table 4. The
631 fitting procedure minimizes the sum of the squared residuals of the normalized total cases,
632 current daily hospitalizations, cumulative deaths, and percentage of total infected individuals
633 currently hospitalized. The first three are present in the data sets while the latter is derived from
634 the estimates of the ratio between infected undetected to infected detected individuals from the

635 CDC Laboratory Seroprevalence Survey Data⁷⁴. Each of these data sets are normalized to
636 maintain equal weight for least squares optimization.

637 While this ratio changes over time, the percentage of infected individuals developing
638 severe symptoms should remain roughly constant throughout the course of the epidemic in the
639 different locations studied.

640 We consider the data sets for outbreaks in MA, NYC, LA, and SJRP, Brazil⁶⁶⁻⁷¹. While
641 each location has testing and fatality information dating back to January, hospitalization data was
642 not included until late March (for NYC and SJRP) and April (for MA and LA). Hence we begin
643 our fitting procedure and testing strategy on 1 April for each of the data sets; by this point, the
644 outbreak is advanced in NYC, substantial in MA, non-negligible, but far from its peak, in LA,
645 and in early stages in SJRP, Brazil. Starting simulations at various stages of the outbreak allows
646 one to see the difference in results between when a testing strategy is administered.

647 In order to determine the effectiveness of the county-based strategy when applied to the
648 state of California, we also fit all of the counties in California with a population greater than
649 1.5% of that of the entire state and with greater than zero deaths. The results do not depend on
650 these selections, but instead suggest a practical criteria to administer limited resources. The
651 fitting is done starting 10 April for these counties, as at this point the outbreak is sufficiently
652 well-documented in each to successfully model. For the county-level data we compute a seven
653 day running average of each of the data sets to which we then fit in order to smooth out
654 fluctuations in the data, likely due to reporting, which are more significant here than in the other
655 data sets considered, as the county populations are smaller and hence discrepancies impact the
656 smoothness of the data more. The fits for each of the counties can be found in Supplementary
657 Fig. 7.

658 As one can see from Fig. 1, these data sets are particularly not smooth, which indicates
659 inefficiencies in reporting. Additionally, it is difficult to gauge their consistency within the dates
660 provided or to compare between locations, as reporting mechanisms changed over time within
661 the same locations. Despite this lack of consistency, our model and fitting mechanism was
662 successful in reproducing the progress of the outbreak in each data set studied.

663

664 **DATA AVAILABILITY**

665 The authors confirm that the data supporting the findings of this study are available within the
666 article and/or its supplementary materials; any other data will be made available upon request.

667

668 **CODE AVAILABILITY**

669 Full code can be found on github: https://github.com/badeaa3/COVID19_Rapid_Testing. The
670 code is written using python with the packages scipy, numpy, lmfit, matplotlib and plotly⁷⁵⁻⁷⁹.

671

672

673

674

675

676

677

678 **References**

- 679 1. Coronavirus Disease (COVID-19) Situation Reports. <https://www.who.int/emergencies/diseases/novel->
680 coronavirus-2019/situation-reports.
- 681 2. Menkir, T. F. *et al.* Estimating the number of undetected COVID-19 cases exported internationally from all of
682 China. *medRxiv* (2020) doi:10.1101/2020.03.23.20038331.
- 683 3. Ivorra, B., Ferrández, M. R., Vela-Pérez, M. & Ramos, A. M. Mathematical modeling of the spread of the
684 coronavirus disease 2019 (COVID-19) taking into account the undetected infections. The case of China.
685 *Commun Nonlinear Sci Numer Simul* 105303 (2020) doi:10.1016/j.cnsns.2020.105303.
- 686 4. Salathé, M. *et al.* COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and
687 isolation. *Swiss Med Wkly* **150**, w20225 (2020).
- 688 5. Lau, H. *et al.* Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global
689 epicenters. *Pulmonology* (2020) doi:10.1016/j.pulmoe.2020.05.015.
- 690 6. Silverman, J. D., Hupert, N. & Washburne, A. D. Using influenza surveillance networks to estimate state-
691 specific prevalence of SARS-CoV-2 in the United States. *Science Translational Medicine* (2020)
692 doi:10.1126/scitranslmed.abc1126.
- 693 7. Böhning, D., Rocchetti, I., Maruotti, A. & Holling, H. Estimating the undetected infections in the Covid-19
694 outbreak by harnessing capture-recapture methods. *Int. J. Infect. Dis.* **97**, 197–201 (2020).
- 695 8. Phipps, S. J., Grafton, R. Q. & Kompas, T. Robust estimates of the true (population) infection rate for COVID-
696 19: a backcasting approach. *Royal Society Open Science* **7**, 200909.
- 697 9. Guglielmi, G. The explosion of new coronavirus tests that could help to end the pandemic. *Nature* **583**, 506–
698 509 (2020).
- 699 10. Thebault, R. *et al.* Hospitalizations set new record as U.S. toll nears 250,000. *Washington Post*.
- 700 11. Wu, K. J. ‘It’s Kitchen Sink Time’: Fast, Less-Accurate Coronavirus Tests May Be Good Enough. *The New*
701 *York Times* (2020).
- 702 12. Mervosh, S. & Fernandez, M. ‘It’s Like Having No Testing’: Coronavirus Test Results Are Still Delayed. *The*
703 *New York Times* (2020).
- 704 13. Wang, Y. *et al.* Kinetics of viral load and antibody response in relation to COVID-19 severity. *J Clin Invest*
705 **130**, 5235–5244 (2020).

- 706 14. Xu, T. *et al.* Clinical features and dynamics of viral load in imported and non-imported patients with COVID-
707 19. *Int J Infect Dis* **94**, 68–71 (2020).
- 708 15. Zhou, R. *et al.* Viral dynamics in asymptomatic patients with COVID-19. *Int J Infect Dis* **96**, 288–290 (2020).
- 709 16. Hu, Z. *et al.* Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close
710 contacts in Nanjing, China. *Sci China Life Sci* **63**, 706–711 (2020).
- 711 17. Gao, Z. *et al.* A Systematic Review of Asymptomatic Infections with COVID-19. *J Microbiol Immunol Infect*
712 (2020) doi:10.1016/j.jmii.2020.05.001.
- 713 18. He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat. Med.* **26**, 672–675
714 (2020).
- 715 19. Baek, Y. H. *et al.* Development of a reverse transcription-loop-mediated isothermal amplification as a rapid
716 early-detection method for novel SARS-CoV-2. *Emerg Microbes Infect* **9**, 998–1007 (2020).
- 717 20. Covid-19 National Testing & Tracing Action Plan. *The Rockefeller Foundation*
718 <https://www.rockefellerfoundation.org/national-covid-19-testing-and-tracing-action-plan/>.
- 719 21. Larremore, D. B. *et al.* Test sensitivity is secondary to frequency and turnaround time for COVID-19
720 surveillance. *medRxiv* (2020) doi:10.1101/2020.06.22.20136309.
- 721 22. Rethinking Covid-19 Test Sensitivity — A Strategy for Containment | NEJM.
722 [https://www.nejm.org/doi/10.1056/NEJMp2025631?url_ver=Z39.88-](https://www.nejm.org/doi/10.1056/NEJMp2025631?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed)
723 [2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed](https://www.nejm.org/doi/10.1056/NEJMp2025631?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed).
- 724 23. Leo, L. Mylab gets commercial approval from ICMR for Covid-19 antigen rapid testing kit. *Livemint*
725 [https://www.livemint.com/news/india/mylab-gets-commercial-approval-from-icmr-for-covid-19-antigen-rapid-](https://www.livemint.com/news/india/mylab-gets-commercial-approval-from-icmr-for-covid-19-antigen-rapid-testing-kit-11595434040321.html)
726 [testing-kit-11595434040321.html](https://www.livemint.com/news/india/mylab-gets-commercial-approval-from-icmr-for-covid-19-antigen-rapid-testing-kit-11595434040321.html) (2020).
- 727 24. Dey, S. Coronavirus testing: Rapid antigen tests now make up nearly half of daily checks | India News - Times
728 of India. *The Times of India* [https://timesofindia.indiatimes.com/india/rapid-antigen-tests-now-make-up-nearly-](https://timesofindia.indiatimes.com/india/rapid-antigen-tests-now-make-up-nearly-half-of-daily-checks/articleshow/77340459.cms)
729 [half-of-daily-checks/articleshow/77340459.cms](https://timesofindia.indiatimes.com/india/rapid-antigen-tests-now-make-up-nearly-half-of-daily-checks/articleshow/77340459.cms).
- 730 25. Vogels, C. B. F. *et al.* Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-
731 probe sets. *Nat Microbiol* (2020) doi:10.1038/s41564-020-0761-6.
- 732 26. Shen, Z. *et al.* Superspreading SARS events, Beijing, 2003. *Emerging Infect. Dis.* **10**, 256–260 (2004).

- 733 27. Peiris, J. S. M. *et al.* Clinical progression and viral load in a community outbreak of coronavirus-associated
734 SARS pneumonia: a prospective study. *Lancet* **361**, 1767–1772 (2003).
- 735 28. Bullard, J. *et al.* Predicting infectious SARS-CoV-2 from diagnostic samples. *Clin. Infect. Dis.* (2020)
736 doi:10.1093/cid/ciaa638.
- 737 29. Giordano, G. *et al.* Modelling the COVID-19 epidemic and implementation of population-wide interventions in
738 Italy. *Nat. Med.* **26**, 855–860 (2020).
- 739 30. Choi, S. & Ki, M. Estimating the reproductive number and the outbreak size of COVID-19 in Korea. *Epidemiol*
740 *Health* **42**, e2020011 (2020).
- 741 31. Wei, Y. Y. *et al.* [Fitting and forecasting the trend of COVID-19 by SEIR(+CAQ) dynamic model]. *Zhonghua*
742 *Liu Xing Bing Xue Za Zhi* **41**, 470–475 (2020).
- 743 32. Yang, Z. *et al.* Modified SEIR and AI prediction of the epidemics trend of COVID-19 in China under public
744 health interventions. *J Thorac Dis* **12**, 165–174 (2020).
- 745 33. Cao, S., Feng, P. & Shi, P. [Study on the epidemic development of COVID-19 in Hubei province by a modified
746 SEIR model]. *Zhejiang Da Xue Xue Bao Yi Xue Ban* **49**, 178–184 (2020).
- 747 34. Huang, R., Liu, M. & Ding, Y. Spatial-temporal distribution of COVID-19 in China and its prediction: A data-
748 driven modeling analysis. *J Infect Dev Ctries* **14**, 246–253 (2020).
- 749 35. Godio, A., Pace, F. & Vergnano, A. SEIR Modeling of the Italian Epidemic of SARS-CoV-2 Using
750 Computational Swarm Intelligence. *Int J Environ Res Public Health* **17**, (2020).
- 751 36. Gatto, M. *et al.* Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment
752 measures. *Proc. Natl. Acad. Sci. U.S.A.* **117**, 10484–10491 (2020).
- 753 37. Hou, C. *et al.* The effectiveness of quarantine of Wuhan city against the Corona Virus Disease 2019 (COVID-
754 19): A well-mixed SEIR model analysis. *J. Med. Virol.* **92**, 841–848 (2020).
- 755 38. Zhou, T. *et al.* Preliminary prediction of the basic reproduction number of the Wuhan novel coronavirus 2019-
756 nCoV. *J Evid Based Med* **13**, 3–7 (2020).
- 757 39. Reno, C. *et al.* Forecasting COVID-19-Associated Hospitalizations under Different Levels of Social Distancing
758 in Lombardy and Emilia-Romagna, Northern Italy: Results from an Extended SEIR Compartmental Model. *J*
759 *Clin Med* **9**, (2020).

- 760 40. Tom, M. R. & Mina, M. J. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. *Clinical*
761 *Infectious Diseases* **71**, 2252–2254 (2020).
- 762 41. Yu, F. *et al.* Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. *Clin. Infect.*
763 *Dis.* **71**, 793–798 (2020).
- 764 42. Rao, S. N., Manissero, D., Steele, V. R. & Pareja, J. A Narrative Systematic Review of the Clinical Utility of
765 Cycle Threshold Values in the Context of COVID-19. *Infect Dis Ther* 1–14 (2020) doi:10.1007/s40121-020-
766 00324-3.
- 767 43. CDC & CDC. Options to Reduce Quarantine for Contacts of Persons with SARS-CoV-2. *Centers for Disease*
768 *Control and Prevention* [https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-options-to-reduce-](https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-options-to-reduce-quarantine.html)
769 [quarantine.html](https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-options-to-reduce-quarantine.html) (2020).
- 770 44. Alizargar, J. Risk of reactivation or reinfection of novel coronavirus (COVID-19). *J. Formos. Med. Assoc.* **119**,
771 1123 (2020).
- 772 45. Batisse, D. *et al.* Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or
773 inflammatory rebound? *J. Infect.* (2020) doi:10.1016/j.jinf.2020.06.073.
- 774 46. Deng, W. *et al.* Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science*
775 (2020) doi:10.1126/science.abc5343.
- 776 47. Ota, M. Will we see protection or reinfection in COVID-19? *Nat. Rev. Immunol.* **20**, 351 (2020).
- 777 48. Victor Okhue, A. Estimation of the Probability of Reinfection With COVID-19 by the Susceptible-Exposed-
778 Infectious-Removed-Undetectable-Susceptible Model. *JMIR Public Health Surveill* **6**, e19097 (2020).
- 779 49. Gu, Y. COVID-19 Projections Using Machine Learning. *COVID-19 Projections Using Machine Learning*
780 <https://covid19-projections.com/>.
- 781 50. Stadlbauer, D. *et al.* Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New
782 York City. *medRxiv* 2020.06.28.20142190 (2020) doi:10.1101/2020.06.28.20142190.
- 783 51. Paltiel, A. D., Zheng, A. & Walensky, R. P. *COVID-19 screening strategies that permit the safe re-opening of*
784 *college campuses*. <http://medrxiv.org/lookup/doi/10.1101/2020.07.06.20147702> (2020)
785 doi:10.1101/2020.07.06.20147702.
- 786 52. Aleta, A. *et al.* Modelling the impact of testing, contact tracing and household quarantine on second waves of
787 COVID-19. *Nature Human Behaviour* **4**, 964–971 (2020).

- 788 53. Wong, M. C. S. *et al.* Stringent containment measures without complete city lockdown to achieve low
789 incidence and mortality across two waves of COVID-19 in Hong Kong. *BMJ Global Health* **5**, e003573 (2020).
- 790 54. Smith, L. E. *et al.* Adherence to the test, trace and isolate system: results from a time series of 21 nationally
791 representative surveys in the UK (the COVID-19 Rapid Survey of Adherence to Interventions and Responses
792 [CORSAIR] study). *medRxiv* 2020.09.15.20191957 (2020) doi:10.1101/2020.09.15.20191957.
- 793 55. Bodas, M. & Peleg, K. Self-Isolation Compliance In The COVID-19 Era Influenced By Compensation:
794 Findings From A Recent Survey In Israel. *Health Affairs* **39**, 936–941 (2020).
- 795 56. Goodnough, A. & Shear, M. D. The U.S.’s Slow Start to Coronavirus Testing: A Timeline. *The New York*
796 *Times* (2020).
- 797 57. Shear, M. D. *et al.* The Lost Month: How a Failure to Test Blinded the U.S. to Covid-19. *The New York Times*
798 (2020).
- 799 58. Kaplan, S. & Thomas, K. Despite Promises, Testing Delays Leave Americans ‘Flying Blind’. *The New York*
800 *Times* (2020).
- 801 59. de Souza, W. M. *et al.* Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil.
802 *Nature Human Behaviour* **4**, 856–865 (2020).
- 803 60. Gostic, K., Gomez, A. C., Mummah, R. O., Kucharski, A. J. & Lloyd-Smith, J. O. Estimated effectiveness of
804 symptom and risk screening to prevent the spread of COVID-19. *eLife* **9**, e55570 (2020).
- 805 61. Zitek, T. The Appropriate Use of Testing for COVID-19. *West J Emerg Med* **21**, 470–472 (2020).
- 806 62. Commissioner, O. of the. Coronavirus (COVID-19) Update: FDA Authorizes First COVID-19 Test for Self-
807 Testing at Home. *FDA* [https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-self-testing-home)
808 [fda-authorizes-first-covid-19-test-self-testing-home](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-self-testing-home) (2020).
- 809 63. Bosch, I. *et al.* Rapid antigen tests for dengue virus serotypes and Zika virus in patient serum. *Sci Transl Med* **9**,
810 (2017).
- 811 64. Callahan, C. *et al.* Nasal-Swab Testing Misses Patients with Low SARS-CoV-2 Viral Loads. *medRxiv* (2020)
812 doi:10.1101/2020.06.12.20128736.
- 813 65. Pinninti, S. *et al.* Comparing Nasopharyngeal and Mid-Turbinate Nasal Swab Testing for the Identification of
814 SARS-CoV-2. *Clin Infect Dis* (2020) doi:10.1093/cid/ciaa882.

- 815 66. Massachusetts Department of Public Health. COVID-19 Response Reporting. *Mass.gov*
816 <https://www.mass.gov/info-details/covid-19-response-reporting>.
- 817 67. California Department of Public Health. COVID-19 Cases - California Open Data.
818 <https://data.ca.gov/dataset/covid-19-cases>.
- 819 68. California Department of Public Health. COVID-19 Hospital Data - California Open Data.
820 <https://data.ca.gov/dataset/covid-19-hospital-data>.
- 821 69. Department of Health and Human Hygiene. COVID-19 Daily Counts of Cases, Hospitalizations, and Deaths |
822 NYC Open Data. [https://data.cityofnewyork.us/Health/COVID-19-Daily-Counts-of-Cases-Hospitalizations-](https://data.cityofnewyork.us/Health/COVID-19-Daily-Counts-of-Cases-Hospitalizations-an/rc75-m7u3)
823 [an/rc75-m7u3](https://data.cityofnewyork.us/Health/COVID-19-Daily-Counts-of-Cases-Hospitalizations-an/rc75-m7u3).
- 824 70. Sao Jose do Rio Preto Public Health Office. *COVID-19 Surveillance Data, Sao Jose do Rio Preto*.
- 825 71. New York State Government. Daily Hospitalization Summary by Region. *New York Forward*
826 <https://forward.ny.gov/daily-hospitalization-summary-region>.
- 827 72. Massachusetts General Hospital Institute for Technology Assessment. COVID-19 Simulator - Methodology.
828 https://www.covid19sim.org/images/docs/COVID-19_simulator_methodology_download_20200507.pdf.
- 829 73. Kermack, W. O. & McKendrick, A. G. Contributions to the mathematical theory of epidemics—I. *Bltm Mathcal*
830 *Biology* **53**, 33–55 (1991).
- 831 74. CDC. Coronavirus Disease 2019 (COVID-19). *Centers for Disease Control and Prevention*
832 <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html> (2020).
- 833 75. SciPy.org — SciPy.org. <https://www.scipy.org/>.
- 834 76. NumPy. <https://numpy.org/>.
- 835 77. Non-Linear Least-Squares Minimization and Curve-Fitting for Python — Non-Linear Least-Squares
836 Minimization and Curve-Fitting for Python. <https://lmfit.github.io/lmfit-py/>.
- 837 78. Matplotlib: Python plotting — Matplotlib 3.3.1 documentation. <https://matplotlib.org/>.
- 838 79. Plotly: The front-end for ML and data science models. <https://plotly.com/>.

839

840

841

842

843 Acknowledgments

844 **General:** We thank Professor Lee Gehrke for critical reading of the manuscript.

845 **Funding:** EN is funded by Tufts University DISC Seed Grant. MLN is supported by a
846 FAPESP grant (#2020/04836-0) and is a CNPq Research Fellow. AFV is supported by a
847 FAPESP Fellow grant (#18/17647-0). GRFC is supported by a FAPESP Fellow grant
848 (#20/07419-0). BHGAM is supported by a FAPESP Scholarship (#19/06572-2). The
849 funders had no role in the design of the study; in the collection, analyses, or interpretation
850 of data; in the writing of the manuscript, or in the decision to publish the results.

851 **Author contributions:** Conceptualization: BBH. Formal analysis: BN, AB, AR, MB,
852 NS, ARG, AV, GCDS, TMILDS, BHGAM, MMM, GRFC, FQ, AFNR, MLN, ENN, IB,
853 BBH. Funding acquisition: IB, BBH. Investigation: BN, AB, AR, MB, NS, ARG, AV,
854 GCDS, TMILDS, BHGAM, MMM, GRFC, FQ, AFNR, MLN, ENN, IB, BBH.
855 Methodology: BN, AB, AR, MB, NS, ARG, AV, GCDS, TMILDS, BHGAM, MMM,
856 GRFC, FQ, AFNR, MLN, ENN, IB, BBH. Project administration: MLN, IB, BBH.
857 Resources: MLN, IB, BBH. Supervision: MB, MLN, ENN, IB, BBH. Validation: BN,
858 AB, AR, MB, ENN, BBH. Visualization: BN, AB, AR, MB, AV, ENN, BBH. Writing—
859 original draft: AR, BBH. Writing—review and editing: BN, AB, AR, MB, NS, ARG,
860 AV, GCDS, TMILDS, BHGAM, MMM, GRFC, FQ, AFNR, MLN, ENN, IB, BBH.

861 **Competing interests:** BN, AB, AR, MB, NS, AG, and BBH are employed by E25Bio
862 Inc. (www.e25bio.com), a company that develops diagnostics for epidemic viruses. BBH
863 and IB are co-founders of E25Bio. AV, GCDS, TMILDS, BHGAM, MMM, GRFC, FQ,
864 AFNR, MLN, and ENN do not have any competing interests.

865

866 **Figures and Tables**

867

868 **TABLES**

869

870 **Table 1. Clinical validation summary for the direct antigen rapid test (DART) for SARS-**

871 **CoV-2 nucleocapsid protein evaluated using 158 retrospectively collected patient nasal**

872 **swab specimens.**

873

All Data Summary								
		qRT-PCR (gene average)					95% Confidence Interval	
		+	-	Total	Sensitivity	82.0%	73.1%	88.9%
DART	+	82	0	82	Specificity	100.0%	93.8%	100.0%
	-	18	58	76	Positive Predictive Value	100.0%		
Total		100	58	158	Negative Predictive Value	76.3%	67.9%	83.0%
					Prevalence	63.3%	55.3%	70.8%
					Overall Agreement	88.6%	82.6%	93.1%

874

875

876

877

878

879

880

881 **Table 2. Clinical validation summary for the SARS-CoV-2 direct antigen rapid test**
 882 **(DART) for SARS-SoC-2 spike glycoprotein evaluated using 121 retrospectively collected**
 883 **patient nasopharyngeal swab specimens.**

884
 885

All Data Summary								
		qRT-PCR (gene average)					95% Confidence Interval	
		+	-	Total	Sensitivity	84.7%	74.3%	92.1%
DART	+	61	7	68	Specificity	85.7%	72.8%	94.1%
	-	11	42	53	Positive Predictive Value	89.7%	81.3%	94.6%
Total		72	49	121	Negative Predictive Value	79.3%	68.7%	86.9%
					Prevalence	59.5%	50.2%	68.3%
					Overall Agreement	85.1%	77.5%	90.9%

886
 887
 888
 889
 890
 891
 892
 893
 894
 895

896 **Table 3. Data summary of direct antigen rapid test (DART) for detection of SARS-CoV-2**
 897 **nucleocapsid protein and DART for detection of SARS-CoV-2 spike glycoprotein**
 898 **performance in comparison to qRT-PCR results.** Sensitivity, specificity, Positive predictive
 899 value, (PPV) negative predictive value (NPV), prevalence, and overall agreement are calculated
 900 for increasing PCR cycle threshold (Ct) values.
 901

		Cycle threshold (Ct) value	Total Cases	DART Positives	DART Negatives	Sensitivity	Specificity
DART (nucleocapsid protein)	SARS-CoV-2 (Gene Average)	< 20	82	24	58	95.8%	100.0%
		< 25	111	53	58	90.6%	100.0%
		< 30	136	78	58	83.3%	100.0%
		< 35	157	99	58	79.8%	100.0%
		< 40	158	100	58	80.0%	100.0%
DART (spike glycoprotein)	SARS-CoV-2 (Gene Average)	< 10	51	2	49	100.0%	85.7%
		< 15	72	23	49	100.0%	85.7%
		< 20	90	41	49	97.6%	85.7%
		< 25	111	62	49	91.9%	85.7%
		< 30	121	72	49	84.7%	85.7%
		< 35	121	72	49	84.7%	85.7%

902
 903
 904
 905
 906
 907
 908
 909
 910
 911

912 **Table 4. Details of parameter values used for *SIDHRE-Q* Model.**

913

Parameter	Details & Statistics			
α	α is rate of transmission between I and S . It is defined as, per day, the probability that an interaction between an undetected infected person and an uninfected person results in a new infection, multiplied by the average number of uninfected people an undetected infected person comes into contact in a day. α is estimated from the data. Units: 1/(days).		Mean	St. Dev.
		MA	0.088	0.051
		LA	0.090	0.034
		NYC	0.067	0.042
		SJRP	0.121	0.042
η	η is rate of transmission between D and S . It is defined as the probability that an interaction between an infected person and an uninfected person results in a new infection, multiplied by the average number of uninfected people a detected infected person comes into contact with in a given day. Units: 1/(days). $\eta = 0.01 \cdot \alpha$ The constant relating η, α accounts for a small but nonzero transmission due to the quarantined (detected) infected population. This value was chosen to be small, assuming an individual in a mandated quarantine will only interact with others with low probability, such as within a household, where complete isolation is difficult to maintain.			
ν	ν is symptomatic detection rate. It is defined as the probability that a symptomatic undetected individual is diagnosed per day. ν is estimated from the data. ν is multiplied by sensitivity (assume benchmark sensitivity 100% for PCR, as used when fitting). Units: 1/days.		Mean	St. Dev.
		MA	0.006	0.005
		LA	0.011	0.006
		NYC	0.0056	0.002
		SJRP	0.015	0.007
ϵ	ϵ is asymptomatic detection rate. It is defined as the probability that an asymptomatic undetected infected individual is diagnosed on a given day. $\epsilon = 0$ while fitting (during PCR symptomatic testing). $\epsilon = (\text{sensitivity}/\text{days between tests})$ when the rapid testing strategy is activated. Units: 1/days.			
λ	λ is undetected recovery rate. It is defined as the probability that an undetected infected individual transitions to the recovered state on a given day. $\lambda = 1/10$, or the inverse of average recovery time ⁷² . Units: 1/days.			
μ	μ is rate of onset of severe symptoms. It is the probability that an infected individual develops severe symptoms on a given day and transitions into the hospitalized state. The flow from D to H is assumed to be independent of the ratio I/D , but comes only from the detected infected population, hence why it is multiplied by $(I + D)/D$. μ is estimated from the data. Units: 1/days.		Mean	St. Dev.
		MA	0.0013	9.5e-4
		LA	0.0016	2.4e-4
		NYC	0.0011	6.6e-4
		SJRP	0.0018	8.0e-4

ρ	<p>ρ is detected recovery rate. It is the probability that a detected infected individual transitions to the recovered state on a given day.</p> <p>$\rho = 1/10$, or the inverse of the average recovery time⁷². Units: 1/days.</p>			
σ	<p>σ is the hospitalized recovery rate. It is the probability that a hospitalized individual transitions to the recovered state on a given day. $\sigma = 1/11$, or the inverse of the average recovery time for a hospitalized individual⁷². Units: 1/days.</p>			
τ	<p>τ is hospitalized rate of death. It is the probability that a hospitalized individual expires on a given day. τ is estimated from the data. Units: 1/days.</p>		Mean	St. Dev.
		MA	0.034	0.012
		LA	0.016	0.004
		NYC	0.036	0.034
		SJRP	0.032	0.045
γ	<p>γ is the false positive rate. It is the probability of entering either of the quarantine states on a given day from either the Susceptible or Recovered populations. $\gamma = 0$ while fitting (during PCR symptomatic testing). $\gamma = (1 - \text{specificity}) \times (1/\text{days between tests})$ when the rapid testing strategy is activated. Units: 1/days.</p>			
ψ	<p>ψ is the rate of exit from quarantine. It is the probability that an individual exits quarantine on a given day. $\psi = 1/10$, or the inverse of the quarantine period for fixed length quarantine. Units: 1/days.</p>			

914

915

916

917

918

919

920

921

922

923

924

925

926 **FIGURES**

927

928 **Fig. 1. Graphical scheme displaying the relationships between the stages of quarantine and**

929 **infection in *SIDHRE-Q* model. **Q-U**, quarantined uninfected; **S**, susceptible (uninfected); **I**,**


930 **infected undetected (pre-testing and infected); **D**, infected detected (infection diagnosis through**

931 **testing); **H**, hospitalized (infected with life threatening symptom progression); **R**, recovered**

932 **(healed); **E**, extinct (dead); and **Q-R**, quarantined recovered (healed but in quarantine by false**

933 **positive testing).**

934



935

936

937

938


939

940

941

942


943 **Fig. 2. COVID-19 Outcomes in 3 US Regions and Brazil as a result of Frequent Rapid**
944 **Testing Protocol using the *SIDHRE-Q* Model.** The Cumulative Detected Infected,
945 Hospitalized, Deceased, Active Infections, Recovered, and Quarantined are modeled over 105
946 days (top to bottom) using reported data from 4 global regions: Massachusetts, Los Angeles,
947 New York City, and São José do Rio Preto in Brazil (left to right). The COVID-19 population
948 spread and outcomes are modeled under a Rapid Testing Protocol (sensitivity 80%, specificity
949 90%) with variable testing frequencies ranging from 1-21 days between tests. This protocol is
950 compared to a symptom-based Rapid Testing protocol and a symptom-based PCR protocol.



Sensitivity: 80.0% Specificity: 90.0%

951
952
953

954 **Fig. 3. Effect of Rapid Testing Protocol under variable testing sensitivities (30%-90%) and**
 955 **increasing frequency under the *SIDHRE-Q* Model.** The Cumulative Infections, Maximum
 956 Simultaneously Hospitalized, and Deceased populations are modeled for Massachusetts, Los
 957 Angeles, New York City, and São José do Rio Preto in Brazil with a 90% test specificity.
 958



959
 960
 961
 962
 963

964 **Fig. 4. Effect of County Based Rapid Testing strategy on COVID-19 outcomes in**
965 **California.** This protocol varies testing frequency in accordance to the number of recorded
966 cases; the threshold for number of active infections which, if reached, signals to commence
967 everyday testing (the highest frequency considered). A Rapid Test with an 80% sensitivity and
968 90% sensitivity versus is used in this deployment strategy. Shown is the total cost per person per
969 day versus the cumulative infections, maximum simultaneously hospitalized, and cumulative
970 deaths with varied thresholds for all of CA is shown. The County Based Rapid Testing strategy
971 is compared to uniform testing, which distributes the same number of total tests used in the
972 county strategy, albeit evenly across each county. The effects of uniform testing are modeled for
973 both a Rapid Testing protocol and a qRT-PCR protocol (A). The effects of County Based Rapid
974 Test Protocol and Uniform PCR Protocol on active infected detected population over time in CA
975 are shown (B). The legend denotes the thresholds at which testing frequency is determined, the
976 testing frequencies, the percent of CA population under the strategy, and the cost per person per
977 day.

978

979

980

981

982


983

984

985

986


987 (A)



988

989

990 (B)



991

992

993